CLRB•benzinga•
Cellectar's Iopofosine I-131 Granted FDA Breakthrough Therapy Designation For Relapsed/Refractory Waldenstrom Macroglobulinemia Based On CLOVER WaM Phase 2 Study Showing 83.6% Response Rate; EMA Guidance On Conditional Approval Pathway Expected By Late Ju
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 4, 2025 by benzinga